2023-08-08 11:45:00
Specific therapy options in the USA
In the USA, two drugs are now specifically approved for the indication “postpartum depression in adults”. One of them, Zuranolone (trade name ZurzuvaeTM), was approved just last week. Like the brexanolone (trade name ZulressoTM), which was approved in 2019, the derivative of the neurosteroid allopregnanolone, zuranolone, is said to act via its function as a positive, allosteric modulator on the GABAA receptor. Such modulators facilitate binding of the natural ligand GABA and thus receptor activation. According to US technical information, the mechanism of action has not yet been fully clarified [3, 4].
1691499200
#Zuranolone #oral #therapy #option #postpartum #depression #receives #approval
